Compare ERII & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | CGEM |
|---|---|---|
| Founded | 1992 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 740.3M | 671.7M |
| IPO Year | 2008 | 2021 |
| Metric | ERII | CGEM |
|---|---|---|
| Price | $14.22 | $10.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $16.50 | ★ $28.13 |
| AVG Volume (30 Days) | 406.0K | ★ 934.6K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.56 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $135,191,000.00 | N/A |
| Revenue This Year | $5.93 | N/A |
| Revenue Next Year | $8.97 | N/A |
| P/E Ratio | $40.32 | ★ N/A |
| Revenue Growth | ★ 0.10 | N/A |
| 52 Week Low | $10.86 | $5.68 |
| 52 Week High | $18.32 | $13.33 |
| Indicator | ERII | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 55.27 |
| Support Level | $14.10 | $10.04 |
| Resistance Level | $14.55 | $11.60 |
| Average True Range (ATR) | 0.35 | 0.66 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 71.26 | 68.72 |
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.